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ABSTRACT 
Aim 
National audits have highlighted suboptimal care for inpatients with diabetes. There is a need 
to design care pathways enabling patients to be seen by the right team at the right time; evidence 
suggests this will lead to improvements in patient outcomes such as mortality and length of 
stay. We previously developed a prediction model using data from University Hospitals 
Birmingham (UHB) to identify inpatients with diabetes at high risk of adverse outcome 
(mortality or excessive length of stay), which could facilitate more effective management of 
these patients by the care team. The aim of this study was to temporally and externally validate 
the model to demonstrate its applicability to other hospital populations within the UK. 
Methods 
Temporal validation was performed using data from UHB; external validation was performed 
using data from Heart of England Foundation Trust (HEFT) and Ipswich Hospital. All adult 
inpatients with diabetes were included. Variables included in the model were age; gender; 
ethnicity; admission type; Intensive Therapy Unit admission; insulin therapy; albumin; sodium; 
potassium; haemoglobin; C-Reactive Protein; estimated Glomerular Filtration Rate; neutrophil 
count. Adverse outcome was defined as excessive length of stay or death. 
Results 
Model discrimination in the temporal and external validation datasets was good. In temporal 
validation using data from UHB, AUC was 0.797 (95% CI 0.785-0.810); sensitivity was 70% 
(95% CI 67-72) and specificity was 75% (95% CI 74-76). In external validation using data 
from HEFT, AUC was 0.758 (95% CI 0.747-0.768); sensitivity was 73% (95% CI 71-74) and 
specificity was 66% (95% CI 65-67). In external validation using data from Ipswich, AUC was 
0.736 (95% CI 0.711-0.761); sensitivity was 63% (95% CI 59-68) and specificity was 69% 
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(95% CI 67-72). These results are comparable to the internally validated model derived at 
UHB. 
Conclusion 
The prediction model to identify patients with diabetes at high risk of developing an adverse 
event while in hospital performed well in temporal and external validation. The externally 
validated prediction model is a novel tool that can be used to improve care pathways for 
inpatients with diabetes. Further research to assess clinical utility is needed. 
 
Keywords 
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What’s new? 
• National audits have highlighted suboptimal care for inpatients with diabetes. 
Evidence suggests targeted review of hospitalised patients with diabetes by a 
specialist team, utilising electronic triggers, could improve clinical outcomes. To date, 
no externally validated tool to identify inpatients with diabetes at risk of adverse 
outcome has been published. 
• In this study we temporally and externally validated a prediction model to identify 
inpatients with diabetes who are at high risk of developing adverse outcomes.  
• Model performance was found to be optimal and sufficient for further evaluation in 
clinical practice, where it may be used to prevent harm, improve clinical outcomes, 
and prioritise care for inpatients with diabetes.  
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Introduction 
Diabetes mellitus is the most common documented comorbidity in a hospital setting, affecting 
17% of all adult admissions.[1] Hospitalised patients with diabetes have high infection rates,[2-
5] longer length of stay (1-3 more days compared to patients without diabetes)[6-8] and 
increased mortality (6.4% higher).[9] Reasons for poor clinical outcomes are less well 
understood but poor glycaemic control and foot disease have been implicated as potential 
reasons.[10-13] In 2009/10, people with diabetes accounted for 11% of NHS expenditure on 
in-hospital care, totalling around £2.5billion.[14] 
Inpatients with diabetes do not receive optimal care: only 30% have their feet examined in the 
first 24 hours and only 60% of those admitted with active foot disease are referred to 
multidisciplinary foot care teams within the first 24 hours of admission,[1] despite these 
standards being recommended by NICE.[15] Furthermore, antidiabetes medication errors 
(occurring in 21% of patient admissions)[1] may result in patient harm, including death.[16] 
Patient surveys and qualitative studies have also highlighted issues around incorrect 
medications, disempowerment, poor meal timing and choice, and inadequate specialist team 
input into diabetes care.[1,17]  
Diabetes specialist teams for inpatient diabetes care may improve patient outcomes and reduce 
length of stay.[18-21] But with rising numbers of inpatients with diabetes there is a need to 
upskill ward staff to manage generic needs of people with diabetes and only refer to specialist 
team for ‘complex needs’. The ‘ThinkGlucose’ campaign[22] recommended criteria for 
inpatient referral to diabetes specialist teams, but, despite widespread campaigning, only 69% 
of patients meeting these criteria are seen by the diabetes specialist team.[1] Very little is 
known regarding whether referrals were timely and if the reason for referral could have been 
avoided by implementing optimal care at an earlier stage.  
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There is a need to develop tools to identify patients in need of diabetes specialist team review 
early during their admission, preferably before they experience an adverse outcome. Such tools 
could be incorporated into the electronic medical record. 
Using data from University Hospitals Birmingham NHS Foundation Trust, our research team 
has previously developed and internally validated a prediction model that identifies 
hospitalised patients with diabetes at risk of adverse outcome while in hospital (mortality or 
excessive length of stay).[23] Unique features of the prediction model are: it does not require 
the reason for admission or information on comorbidities, as routinely available data including 
blood results are used to predict risk; and it has the ability to identify patients at risk of adverse 
outcome within the first 24 hours of admission. 
The aim of this study was to temporally and externally validate this prediction model, in order 
to determine whether it performs equally well in more recent data and in other hospital settings 
before trialling for clinical practice.  
Methods 
Setting and data sources 
The prediction model was developed using data from University Hospitals Birmingham NHS 
Foundation Trust (UHB) from 2007 to 2010.[23] Temporal validation was carried out using 
inpatient data from 1st January to 31st December 2014 from University Hospitals Birmingham 
NHS Foundation Trust (UHB). External validation was carried out using inpatient data from 
1st January to 31st December 2014 from Heart of England NHS Foundation Trust (HEFT) and 
inpatient data from 1st January to 30th June 2014 from Ipswich Hospital.  
UHB is a tertiary hospital in the West Midlands with over 1200 beds, providing secondary care 
to an ethnically diverse population. HEFT is a large hospital trust, comprised of several 
hospitals across the West Midlands (Heartlands, Good Hope and Solihull), with a total of more 
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than 1550 beds; the trust serves an ethnically and socio-economically diverse range of 
communities. Ipswich Hospital is located in the East of England; it is a district hospital with 
approximately 800 beds, and provides secondary care to a slightly older, less deprived and less 
ethnically diverse population. 
Participants 
All patients with diabetes aged 16 and over were included in the analysis. For HEFT, data was 
only available for patients aged 18 years and over. 
Outcome definition 
Adverse outcome was a composite of excessive length of stay or death.[23] Excessive length 
of stay was defined as an excess length of stay greater than the 75th centile for all admissions 
for people with diabetes. Excess length of stay was defined as the difference between the actual 
length of stay for the diabetic inpatient admission and the median length of stay calculated in 
all inpatients with diabetes admitted in the same primary diagnosis category. In sensitivity 
analysis, median length of stay was calculated in inpatients without diabetes (UHB only; this 
data was not available for HEFT and Ipswich). Primary diagnosis category was defined using 
the 260 group categories in the Healthcare Research and Quality clinical classification software 
(CCS).[24] 
Definitions of variables 
Diabetes was defined using discharge diagnostic codes and prescription data. The diagnostic 
codes used to indicate diabetes were International Classification of Diseases version 10 (ICD-
10) codes E10–E14 or any of their sub-classifications. Additionally, patients were categorised 
as having diabetes if they were on any of type of insulin, sulphonylurea, biguanide or other 
antidiabetes drug, excluding patients on metformin alone with a discharge diagnostic code for 
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polycystic ovarian syndrome or patients who received short- or rapid-acting insulin alone.[25] 
All inpatients with diabetes were included irrespective of primary diagnosis. 
The variables included in the model were: age; sex; ethnicity; admission type (elective or 
emergency); intensive therapy unit (ITU) admission (binary); insulin therapy (binary); 
presence/absence of foot disease (binary); and the following clinical pathology test results: 
albumin, sodium, potassium, haemoglobin, C-Reactive Protein (CRP), estimated Glomerular 
Filtration Rate (eGFR), neutrophil count. Insulin therapy was defined as one or more 
prescription for insulin during the admission; this data was not available for Ipswich, therefore 
insulin prescription prior to admission was used. Presence of foot disease was identified using 
both discharge diagnostic codes and OPCS Classification of Interventions and Procedures 
codes recorded at any time during the admission.[13] In instances where a patient had multiple 
blood tests during a single admission, the earliest test result for the admission was used. 
Normal blood test results were defined as follows: albumin ≥ 35 g/L; sodium 135–144 mmol/L; 
potassium 3–5.9 mmol/L; haemoglobin ≥ 12 g/dL; CRP 0–9 mg/L; eGFR ≥ 90 mL/min/1.73 
m2; neutrophil count <7.9 × 109/L. 
Definition of model 
Coefficients of the logistic regression model are presented in Supplementary Table 1. 
Analysis 
For patients with multiple admissions, a single, randomly selected admission was included in 
the analysis; a sensitivity analysis was carried out including all admissions. Data were complete 
for all variables except clinical pathology (blood) test results. Missing clinical pathology test 
results were replaced using multiple imputation (10 imputations); this was performed using 
chained equations and predictive mean matching. In additional sensitivity analysis, missing test 
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results were replaced with values in the normal range to better reflect use of the model in a 
hospital setting. 
Performance assessment 
Model discrimination was assessed by plotting a receiver operating characteristic (ROC) curve 
and calculating area under the curve (AUC, or Harrell’s C-statistic). Sensitivity, specificity, 
and positive and negative predictive values were calculated at a ≥ 25% predicted chance of 
adverse outcome; this was found to be the optimal threshold, at which the sum of sensitivity 
and specificity was maximal (Youden’s index), during development of the model. Test 
statistics generated from the 10 imputed datasets were combined using Rubin’s rule. Model 
calibration was assessed by plotting predicted probabilities of outcome against observed 
probabilities of outcome, by decile, with overlaid LOWESS (locally weighted scatterplot 
smoothing) curve. 
Results 
Temporal validation 
6,533 inpatients with diabetes contributing to a total of 11,019 hospital admissions at UHB 
were included in the temporal validation analysis. 27.5% (n = 1,797) of these patients had an 
adverse outcome: 1,529 patients had an excessive length of stay, 164 died, and 104 had an 
excessive length of stay ending in death. Baseline patient characteristics are presented in Table 
1 (see also Supplementary Table 2). Patient characteristics in the UHB temporal validation 
dataset (2014) were comparable to those in the original UHB model development dataset 
(2007–2010), with the exception of the proportion of patients prescribed insulin, which had 
decreased from 67.9% and 47.8% (2007–2010) to 47.5% and 20.6% (2014) in patients with 
and without adverse outcome respectively. Additionally, blood test results were more complete 
in the 2014 data (Supplementary Table 3). 
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In temporal validation, replacing missing values using multiple imputation, model 
discrimination was good: AUC was 0.797 (95% CI 0.785–0.810). At a threshold of ≥ 25% 
predicted probability of adverse event, sensitivity was 69.5% (95% CI 67.3–71.6) and positive 
predictive value (PPV) was 51.3% (95% CI 49.2–53.3) (Table 2). 
In the three sensitivity analyses, replacing missing values with values in the normal range, 
calculating median length of stay in non-diabetic inpatients, and using all admissions for 
inpatients with diabetes (rather than just a single randomly selected admission for each patient) 
made very little difference to model performance (Table 2, Figure 2, and Supplementary Tables 
4 and 5).  
Model calibration was good, with the LOWESS curve in close proximity to the 45 degree line, 
i.e. predicted probabilities were similar to observed probabilities (Figure 1d). 
External validation 
10,690 inpatients with diabetes contributing to a total of 16,568 hospital admissions at HEFT, 
and 1,885 patients contributing to a total of 2,554 hospital admissions at Ipswich were included 
in the external validation analyses. In the HEFT dataset, 27.8% (n = 2,973) of patients had an 
adverse outcome: 2,423 patients had an excessive length of stay, 301 died, and 249 had an 
excessive length of stay ending in death. In the Ipswich dataset, 27.4% (n = 517) of patients 
had an adverse outcome: 425 patients had an excessive length of stay, 46 died, and 46 had an 
excessive length of stay ending in death. Baseline patient characteristics are presented in Table 
1 (see also Supplementary Table 2). In both the HEFT and Ipswich datasets, there were more 
emergency admissions and fewer ICU admissions compared to UHB. Fewer HEFT patients 
had foot disease. Insulin treatment rates were lower at Ipswich, with little difference between 
rates in patients with or without adverse outcome. 
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In the HEFT external validation dataset, replacing missing values using multiple imputation, 
AUC was 0.758 (95% CI 0.747–0.768). At a threshold of ≥ 25% predicted probability of 
adverse event, sensitivity was 72.6% (95% CI 70.9–74.2) and PPV was 45.1% (95% CI 43.7–
46.5) (Table 2). 
In the Ipswich external validation dataset, replacing missing values using multiple imputation, 
AUC was 0.736 (95% CI 0.711–0.761). At a threshold of ≥ 25% predicted probability of 
adverse event, sensitivity was 63.4% (95% CI 59.1–67.6) and PPV was 43.8% (95% CI 40.3–
47.5) (Table 2). 
In two sensitivity analyses, missing values were replaced with values in the normal range, and 
model performance was assessed in all admissions for inpatients with diabetes (rather than 
using a single randomly selected admission for each patient); this made little difference to the 
model performance (Table 2, Figures 1b-c and 2, and Supplementary Table 5).  
Model calibration was good in both datasets (Figures 1e-f). 
Discussion 
Our previously published model performed well with an AUC of 0.80, 0.76 and 0.74 in UHB, 
HEFT and Ipswich respectively. It was able to identify (sensitivity) two thirds to three quarters 
of patients at high risk of adverse outcomes (63% at Ipswich Hospital, 70% at UHB and 73% 
at HEFT). Among those who were predicted by the model to have an adverse outcome, 44% 
in Ipswich Hospital, 45% in HEFT and 51% at UHB (positive predictive value) went on to 
have an adverse event defined as death or excessive length of stay. The results were robust in 
our sensitivity analyses; performance improved when missing values were replaced with 
normal values, which better reflects implementation in a clinical setting. 
Prediction models can become outdated with change in population demography, better linkage 
of data systems, better therapeutic options and care pathways, and improvement in data 
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recording. However, model performance at UHB was similar after nearly 5 years, with an AUC 
of 0.802 (95% CI 0.795–0.808) and 0.804 (95% CI 0.792–0.816)[23] in the development and 
temporal validation datasets respectively. Specificity increased from 70% in the derivation 
dataset to 75% in the temporal validation dataset, and PPV remained similar, changing from 
49% to 51%. Sensitivity was lower at 70% in temporal validation compared to 76% in the 
derivation dataset. This can be attributed in part to improved linkage of Electronic Medical 
Record (EMR) data to Patient Administrative System data in recent years (> 95% compared to 
77% previously[25]). This means patients who were less ill may not have been included in the 
model development dataset as they would have been discharged before being entered into the 
EMR, leading to some dissimilarity between the patient cohorts. 
Model performance in Ipswich Hospital was slightly inferior. This may be explained by the 
fact that only data from the first six months of the calendar year was available; the population 
was less ethnically diverse compared to the other two hospitals; and the definition of insulin 
differed. The observed differences in insulin use may be attributable to a difference in the 
prescription information used (insulin prior to admission rather than during) and to the method 
of data recording (use of in-house insulin recording rather than electronic prescription data, as 
at UHB and HEFT). However, the performance parameters were still comparable to many 
clinically utilised prediction models such as the Rockall score for outcomes of upper 
gastrointestinal bleed.[26] 
Overall, the results of this analysis demonstrate that the model is both temporally and externally 
valid: it performed well in both more recent data from the original hospital (UHB) and in other 
hospitals with sociodemographically different inpatient populations (HEFT, Ipswich). This 
indicates that the model is applicable in diverse and varying hospital populations within the 
UK. 
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The strengths of the study include external validation across two distinctly different hospital 
settings, datasets with large number of patients and events, robust methodology including 
number of sensitivity analyses, and being the first study to derive and validate a prediction 
model to identify adverse events in hospitalised patients with diabetes based on routinely 
collected data close to the time of admission.  Only two other algorithms that aim to identify 
patients at risk of hypoglycaemia exist for inpatients with diabetes, but these were not 
externally validated.[27-28] However, validation is limited to hospitals in the United Kingdom, 
and data from Ipswich Hospital had limitations that prevented us from optimally demonstrating 
the performance in a District General Hospital setting. 
One of the unique features of the model is that it utilises routinely collected data on admission 
and can therefore be incorporated into EMR without any additional information needs. 
However, the model could only be incorporated where there are robust EMR; currently only a 
third of UK hospitals are fully utilising EMR, while a further 31% are making partial use of 
EMR.[1] Nevertheless the UK government has encouraged hospitals to procure EMR and 
replace paper-based medical records within the next few years.[29] Therefore it is the right 
time to develop and evaluate novel tools that could result in better clinical outcomes and 
healthcare efficiency.  
The model has potential clinical utility and could help shape care pathways for hospitalised 
patients with diabetes. We propose to develop electronic care pathways and test direct and 
indirect triggers that could alert diabetes specialist teams or other health professionals to take 
timely actions. Direct triggers will include alerts for recurrent or severe hypoglycaemia, insulin 
infusions over 48 hours and persistent hyperglycaemia. The prediction model will serve as an 
indirect trigger and will aim to identify patients at high risk of adverse event (Figure 3). If the 
model were implemented, about half of people with diabetes flagged up by a system like this 
would experience an adverse outcome. Furthermore most of those who will experience an 
Adderley N et al. 
13 
 
adverse outcome would be flagged up. This suggests the model might be useful in identifying 
those individuals who might benefit from additional input. Clinical judgement might play a 
further role in identifying those flagged up who were most likely to benefit from input. 
However, it should be noted that, at present, there is a lack of strong evidence regarding 
whether or not specialist inpatient diabetes teams can reduce mortality; this is an area that 
requires further research. 
One criticism of the model is that it may identify ill patients who might not particularly benefit 
from review by the diabetes specialist team. Another criticism is that most covariates and the 
outcomes in the model are not diabetes-specific, and the model may therefore perform well in 
other chronic conditions to predict length of stay and mortality. However, we have shown 
parameters in the model can predict hypoglycaemia[28] and therefore it is reasonable to 
hypothesize that a care pathway with risk stratification can enable harm reduction and better 
clinical end points for inpatients with diabetes. For example, an algorithm for hypoglycaemia 
developed and implemented in a hospital in the United States resulted in 68% reduction in 
severe hypoglycaemic episodes.[27]  
Conclusion 
The prediction model to identify patients with diabetes at high risk of developing an adverse 
outcome while in hospital performed well when externally validated. The model now needs to 
be tested for clinical utility in hospitalised patients with diabetes in England. If found to be of 
clinical benefit, it should be further externally validated in other countries with EMR before 
implementation in their hospital setting.  
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Figure legends 
Figure 1. ROC curves for a. UHB (temporal validation), b. HEFT (external validation), and c. 
Ipswich (external validation); and calibration plots for d. UHB, e. HEFT, and f. Ipswich 
(replacing missing data with values in the normal range). 
Figure 2. Confusion matrices showing actual and predicted numbers of adverse outcomes for 
a. UHB, b. HEFT, and c. Ipswich (replacing missing data with values in the normal range). 
Figure 3. Proposed electronic triggers enhanced care pathway for hospitalised patients with 
diabetes. 
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Table 1. Baseline characteristics for patients with and without adverse outcome in each 
of the three hospital datasets 
Patient 
characteristics 
UHB 
(temporal validation) 
HEFT 
(external validation) 
Ipswich 
(external validation) 
No adverse 
outcome 
Adverse 
outcome 
No adverse 
outcome 
Adverse 
outcome 
No adverse 
outcome 
Adverse 
outcome 
(n = 4736) (n = 1797) (n =7716 ) (n = 2974) (n = 1368) (n = 517) 
Age category n (%)             
16-44* 462 (9.8) 77 (4.3) 870 (11.3) 116 (3.9) 115 (8.4) 4 (0.8) 
45-54 703 (14.8) 159 (8.9) 1000 (13.0) 190 (6.4) 118 (8.6) 26 (5.0) 
55-64 997 (21.1) 306 (17.0) 1484 (19.2) 348 (11.7) 181 (13.2) 52 (10.1) 
65-74 1183 (25.0) 450 (25.0) 1761 (22.8) 616 (20.7) 335 (24.5) 102 (19.7) 
75-84 1000 (21.1) 525 (29.2) 1881 (24.4) 1045 (35.1) 399 (29.2) 195 (37.7) 
≥ 85 391 (8.3) 280 (15.6) 720 (9.3) 659 (22.2) 220 (16.1) 138 (26.7) 
Sex n (%)             
Male 2645 (55.9) 973 (54.2) 4037 (52.3) 1489 (50.1) 763 (55.8) 269 (52.0) 
Female 2091 (44.2) 824 (45.9) 3679 (47.7) 1485 (49.9) 605 (44.2) 248 (48.0) 
Ethnicity n (%)             
White 3105 (65.6) 1286 (71.6) 5273 (68.3) 2251 (75.7) 1107 (80.9) 433 (83.8) 
South Asian† 1025 (21.6) 334 (18.6) 1737 (22.5) 488 (16.4) 20 (1.5) 3 (0.6) 
Black 294 (6.2) 114 (6.3) 314 (4.1) 119 (4.0) 17 (1.2) 6 (1.2) 
Other/missing 312 (6.6) 63 (3.5) 392 (5.1) 116 (3.9) 224 (16.4) 75 (14.5) 
IMD deprivation quintile n (%)            
Least deprived 1 232 (4.9) 89 (5.0) 893 (11.6) 360 (12.1) 225 (16.5) 109 (21.1) 
2 317 (6.7) 137 (7.6) 808 (10.5) 335 (11.3) 300 (21.9) 107 (20.7) 
3 898 (19.0) 357 (19.9) 969 (12.6) 397 (13.4) 384 (28.1) 140 (27.1) 
4 911 (19.2) 348 (19.4) 1071 (13.9) 448 (15.1) 177 (12.9) 61 (11.8) 
Most deprived 5 2293 (48.4) 824 (45.9) 3947 (51.2) 1421 (47.8) 277 (20.3) 94 (18.2) 
Unknown 85 (1.8) 42 (2.3) 28 (0.4) 13 (0.4) 5 (0.4) 6 (1.2) 
Type of admission n (%)           
Elective 1299 (27.4) 253 (14.1) 1345 (17.4) 258 (8.7) 290 (21.2) 32 (6.2) 
Emergency 3437 (72.6) 1544 (85.9) 6371 (82.6) 2716 (91.3) 1078 (78.8) 485 (93.8) 
Modified Charlson comorbidity score n (%)         
0 2573 (54.3) 588 (32.7) 4653 (60.3) 1084 (36.5) 734 (53.7) 172 (33.3) 
1 840 (17.7) 331 (18.4) 1427 (18.5) 574 (19.3) 256 (18.7) 108 (20.9) 
≥2 1323 (27.9) 878 (48.9) 1636 (21.2) 1316 (44.3) 378 (27.6) 237 (45.8) 
Insulin use n (%)             
Yes 974 (20.6) 854 (47.5) 1929 (25.0) 1121 (37.7) 201 (14.7) 73 (14.1) 
No 3762 (79.4) 943 (52.5) 5787 (75.0) 1853 (62.3) 1167 (85.3) 444 (85.9) 
ITU care n (%)             
Yes 132 (2.8) 350 (19.5) 25 (0.3) 82 (2.8) 19 (1.4) 34 (6.6) 
No 4604 (97.2) 1447 (80.5) 7691 (99.7) 2892 (97.2) 1349 (98.6) 483 (93.4) 
Foot disease n (%)             
Yes 332 (7.0) 275 (15.3) 273 (3.5) 211 (7.1) 90 (6.6) 79 (15.3) 
No 4404 (93.0) 1522 (84.7) 7443 (96.5) 2763 (92.9) 1278 (93.4) 438 (84.7) 
*For HEFT, data was only available for adults aged 18 years and over. †South Asian: Bangladeshi, 
Indian, Pakistani. IMD: Index of Multiple Deprivation. ITU: Intensive therapy unit. 
  
Adderley N et al. 
22 
 
Table 2. Model performance (randomly selected single patient admission for patients with multiple admissions) 
Hospital Missing 
values N AUC (95% CI) 
Sensitivity 
% (95% CI) 
Specificity 
% (95% CI) 
PPV 
% (95% CI) 
NPV 
% (95% CI) 
UHB - temporal validation             
Median los calculated in 
diabetic patients only 
mi 6533 0.797 (0.785–0.810) 69.5 (67.3–71.6) 74.9 (73.7–76.2) 51.3 (49.2–53.3) 86.6 (85.6–87.7) 
Normal 6533 0.808 (0.797–0.820) 69.0 (66.8–71.1) 77.1 (75.9–78.3) 53.3 (51.3–55.4) 86.7 (85.7–87.8) 
HEFT - external validation             
Median los calculated in 
diabetic patients only 
mi 10690 0.758 (0.747–0.768) 72.6 (70.9–74.2) 66.0 (64.9–67.0) 45.1 (43.7–46.5) 86.2 (85.3–87.1) 
Normal 10690 0.760 (0.750–0.770) 69.2 (67.5–70.9) 70.2 (69.1–71.2) 47.2 (45.7–48.7) 85.5 (84.7–86.4) 
Ipswich - external validation             
Median los calculated in 
diabetic patients only 
mi 1885 0.736 (0.711–0.761) 63.4 (59.1–67.6) 69.3 (66.8–71.7) 43.8 (40.3–47.5) 83.4 (81.1–85.5) 
Normal 1885 0.746 (0.722–0.770) 62.5 (58.1–66.7) 71.3 (68.9–73.7) 45.2 (41.5–48.9) 83.4 (81.2–85.5) 
 Normal: missing blood test results replaced by values in the normal range; mi: missing blood test results replaced using multiple imputation. 
